Gut Molecule Imidazole Propionate Accelerates Alzheimer’s Disease Progression
A molecule produced by digestive tract bacteria may heighten the risk of Alzheimer’s disease and accelerate cognitive decline in dementia patients, according to new research published in Nature Communications. Researchers at the University of Wisconsin-Madison found that imidazole propionate (ImP), a compound generated when gut microbes break down specific amino acids, travels from the intestines through the bloodstream and reaches the brain, where it worsens the accumulation of neurotoxic proteins.
Nearly a decade ago, a research team led by University of Wisconsin-Madison professors Barbara Bendlin and Federico Rey discovered that the microbial makeup of the human intestine differs between healthy individuals and those diagnosed with Alzheimer’s disease. Since that initial observation, the laboratory has investigated how intestinal microbiota influence neurological health. Their recent study links a specific bacterial byproduct directly to the hallmark pathology of cognitive disorders.
How Intestinal Microbes Produce ImP
Microorganisms residing in the human gut manufacture imidazole propionate while generating energy from histidine, an essential amino acid abundant in protein-rich foods. Although ImP-producing bacteria are present in a large fraction of the population, their overall abundance varies widely among individuals. Federico Rey, a professor of bacteriology at the University of Wisconsin-Madison, notes that a microbe does not need to be abundant to exert a significant physiological impact on the human host. Once synthesized in the digestive system, ImP enters the circulatory system and disperses throughout the body. Previous medical investigations have connected the identical compound to type 2 diabetes and coronary artery disease.
Protein Accumulation and Rapid Cognitive Decline
To determine how the compound affects neural tissue, researchers administered ImP to mouse models. The experiments revealed that the molecule promoted the accumulation of abnormal beta-amyloid and tau proteins, which are the two primary pathological hallmarks of Alzheimer’s disease. According to Rey, this biological cascade results in the death of neurons, matching a key feature observed in human patients. To confirm these findings in humans, the team analyzed blood samples from nearly 1,200 participants enrolled in the Wisconsin Registry for Alzheimer’s Prevention and studies at the Wisconsin Alzheimer’s Disease Research Center. Participants exhibiting higher blood concentrations of ImP displayed a greater likelihood of carrying biological markers associated with impaired neuronal function. By reviewing longitudinal cognitive testing data, investigators established that volunteers with the highest circulating levels of ImP experienced significantly faster cognitive decline over time.
Genetic Variations Influence Blood Concentration Levels
The investigation also uncovered a genetic variation present in approximately 43 percent of study participants that correlates with substantially elevated levels of ImP in the bloodstream. Scientists suspect this genetic difference alters how efficiently the kidneys filter and remove the compound from circulation. Because prior large-scale genetic studies linked this exact genetic variation to an increased risk of Alzheimer’s disease, the new discovery provides a biological mechanism explaining that connection.
Targeting the Compound for Future Treatments
Developing prevention strategies by altering the human diet remains challenging. Because histidine is an essential amino acid required for human health and is found in many common protein sources, Barbara Bendlin, a professor of medicine in the UW School of Medicine and Public Health, points out that avoiding specific foods like eggs or red meat is insufficient to lower ImP levels. Instead, researchers aim to develop pharmaceutical treatments that inhibit ImP production or block its circulation. Bendlin compares the potential therapeutic approach to statins used to manage cholesterol, suggesting that a future enzyme inhibitor could reduce ImP concentrations in the blood and slow the progression of cognitive decline for many patients. Additional contributions to the study came from researchers at the University of California, Los Angeles and the University of Gothenburg.
Frequently Asked Questions About Gut Microbes and Alzheimer’s Risk
How does imidazole propionate reach the brain from the gut?
Once specific bacteria in the digestive system produce imidazole propionate from the amino acid histidine, the compound enters the bloodstream and travels via circulation to other organs, eventually crossing into the brain.
Can changing your diet eliminate imidazole propionate in the body?
Dietary modification alone cannot stop ImP production because histidine is an essential amino acid found in many protein-rich foods that the human body requires for normal function.
What role does genetics play in ImP blood levels?
A genetic variation found in about 43 percent of study participants is associated with significantly higher ImP concentrations in the bloodstream, likely because it affects how effectively the kidneys clear the compound.